Is Ozempic Face a real thing?

Who hasn't felt bombarded by the relentless marketing of the latest wonder drug for weight loss? It's like every time you scroll through your social media, there's another jaw-dropping transformation from a celebrity or public figure. Oprah looked great at 'The Color Purple' premiere and has credited her slender figure to a semaglutide drug. Semaglutide is a class of medications known as glucagon-like peptide 1 (GLP1) receptors, more commonly known as Ozempic and Wegovy in the public eye.

 

In this week's podcast, Dr. Patel and I talk about Ozempic—how it's used, who it's good for, and its skin-related side effects like loose skin and hair loss.

 

In this episode:

 

- What is semaglutide/Ozempic?  (6:01)

 

- How are these medications administered? (9:24)

 

- Various ways to manage 'Ozempic face'? (15:13)

 

- Does the 'Ozempic face' go away? (19:39)

 

- Alternative for weight loss beyond this medication (24:03)

 

Forum Patel, MD joined Arya Derm after completing a prestigious fellowship in Cosmetics & Laser Surgery accredited by the American Society of Dermatologic Surgery at Union Square Laser Dermatology in New York City. Formally trained in medical and cosmetic dermatology, Dr. Patel is passionate about helping her patients improve on their already existing foundation to achieve the best version of themselves. She also believes that preventive care is fundamental to healthy aging when it comes to skin care and cancer screening.

 

Find Dr. Patel here:

 

https://www.instagram.com/dr.forum_patel/

 

https://www.aryaderm.com

 

Follow Dr. Mina here:- 

https://instagram.com/drminaskin

 

For more great skin care tips, subscribe to The Skin Real Podcast or visit www.theskinreal.com 

Baucom & Mina Derm Surgery, LLC 
Email - scheduling@atlantadermsurgery.com Contact - (404) 844-0496 
Instagram - @baucomminamd

Thanks for listening!

The content of this podcast is for entertainment, educational, and informational purposes and does not constitute formal medical advice.